126 related articles for article (PubMed ID: 19799084)
1. [Expressions of RASSF1A, Galectin-3 and TPO mRNA in papillary thyroid carcinoma and their clinical significance].
Xu MR; Chen Y; Zhou SR; Chi MM; Chen SL; Liu LY
Zhonghua Zhong Liu Za Zhi; 2009 May; 31(5):356-60. PubMed ID: 19799084
[TBL] [Abstract][Full Text] [Related]
2. BRAFV600E mutation, but not RET/PTC rearrangements, is correlated with a lower expression of both thyroperoxidase and sodium iodide symporter genes in papillary thyroid cancer.
Romei C; Ciampi R; Faviana P; Agate L; Molinaro E; Bottici V; Basolo F; Miccoli P; Pacini F; Pinchera A; Elisei R
Endocr Relat Cancer; 2008 Jun; 15(2):511-20. PubMed ID: 18509003
[TBL] [Abstract][Full Text] [Related]
3. Thyroid peroxidase and galectin-3 immunostaining in differentiated thyroid carcinoma with clinicopathologic correlation.
Savin S; Cvejic D; Isic T; Paunovic I; Tatic S; Havelka M
Hum Pathol; 2008 Nov; 39(11):1656-63. PubMed ID: 18657294
[TBL] [Abstract][Full Text] [Related]
4. [Detection of cytokeratin 19 and thyroperoxidase expressions in the diagnosis of thyroid diseases].
Yang QX; Shao CK; Feng ZY; Huang BQ; Han AJ; Xiong M; Zhao WL; Wu TT
Di Yi Jun Yi Da Xue Xue Bao; 2005 Jun; 25(6):678-81. PubMed ID: 15958307
[TBL] [Abstract][Full Text] [Related]
5. Expression of iodine metabolism genes in human thyroid tissues: evidence for age and BRAFV600E mutation dependency.
Espadinha C; Santos JR; Sobrinho LG; Bugalho MJ
Clin Endocrinol (Oxf); 2009 Apr; 70(4):629-35. PubMed ID: 18710471
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic significance of CK19, RET, galectin-3 and HBME-1 expression for papillary thyroid carcinoma.
Zhu X; Sun T; Lu H; Zhou X; Lu Y; Cai X; Zhu X
J Clin Pathol; 2010 Sep; 63(9):786-9. PubMed ID: 20644217
[TBL] [Abstract][Full Text] [Related]
7. [Expression and clinical significance of galectin-3 in well-differentiated thyroid carcinoma].
Ouyang D; Chen FJ; Wei MW; Yang AK; Chen ZQ; Li QL; Chen YF
Ai Zheng; 2005 Nov; 24(11):1367-71. PubMed ID: 16552965
[TBL] [Abstract][Full Text] [Related]
8. Expression of papillary thyroid carcinoma-associated molecular markers and their significance in follicular epithelial dysplasia with papillary thyroid carcinoma-like nuclear alterations in Hashimoto's thyroiditis.
Ma H; Yan J; Zhang C; Qin S; Qin L; Liu L; Wang X; Li N
Int J Clin Exp Pathol; 2014; 7(11):7999-8007. PubMed ID: 25550843
[TBL] [Abstract][Full Text] [Related]
9. [Usefulness of CK19, HBME-1 and galectin-3 expressions in differential diagnosis of thyroid papillary microcarcinoma from benign lesions].
Tong J; Wang Y; Da JP
Zhonghua Zhong Liu Za Zhi; 2011 Aug; 33(8):599-604. PubMed ID: 22325220
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical loss of thyroid peroxidase in papillary thyroid carcinoma: strong suppression of peroxidase gene expression.
Tanaka T; Umeki K; Yamamoto I; Sugiyama S; Noguchi S; Ohtaki S
J Pathol; 1996 May; 179(1):89-94. PubMed ID: 8691351
[TBL] [Abstract][Full Text] [Related]
11. The use of a combination of galectin-3 and thyroid peroxidase for the diagnosis and prognosis of thyroid cancer.
Weber KB; Shroyer KR; Heinz DE; Nawaz S; Said MS; Haugen BR
Am J Clin Pathol; 2004 Oct; 122(4):524-31. PubMed ID: 15487449
[TBL] [Abstract][Full Text] [Related]
12. Galectin-3 and CD44v6 positivity by RT-PCR method in fine needle aspirates of benign thyroid lesions.
Matesa N; Samija I; Kusić Z
Cytopathology; 2007 Apr; 18(2):112-6. PubMed ID: 17397496
[TBL] [Abstract][Full Text] [Related]
13. [Galectin-3 in diagnosis of thyroid cancer].
Semenov DIu; Pozharisskiĭ KM; Boriskova ME; Pankova PA; Mukhina MS; Feshchenko NS
Vopr Onkol; 2008; 54(3):321-3. PubMed ID: 18652236
[TBL] [Abstract][Full Text] [Related]
14. Expression of Galectin-3 and Galectin-7 in thyroid malignancy as potential diagnostic indicators.
Than TH; Swethadri GK; Wong J; Ahmad T; Jamil D; Maganlal RK; Hamdi MM; Abdullah MS
Singapore Med J; 2008 Apr; 49(4):333-8. PubMed ID: 18418527
[TBL] [Abstract][Full Text] [Related]
15. Utility of galectin 3 expression in thyroid aspirates as a diagnostic marker in differentiating benign from malignant thyroid neoplasms.
Aron M; Kapila K; Verma K
Indian J Pathol Microbiol; 2006 Jul; 49(3):376-80. PubMed ID: 17001889
[TBL] [Abstract][Full Text] [Related]
16. Galectin-3 expression in papillary thyroid carcinoma: relation to histomorphologic growth pattern, lymph node metastasis, extrathyroid invasion, and tumor size.
Cvejic DS; Savin SB; Petrovic IM; Paunovic IR; Tatic SB; Havelka MJ
Head Neck; 2005 Dec; 27(12):1049-55. PubMed ID: 16155918
[TBL] [Abstract][Full Text] [Related]
17. Differential expression of thyroperoxidase mRNA splice variants in human thyroid tumors.
Le Fourn V; Ferrand M; Franc JL
Biochim Biophys Acta; 2004 Jun; 1689(2):134-41. PubMed ID: 15196594
[TBL] [Abstract][Full Text] [Related]
18. TPO gene mutations associated with thyroid carcinoma: Case report and literature review.
Zhu H; Peng YG; Ma SG; Liu H
Cancer Biomark; 2015; 15(6):909-13. PubMed ID: 26406404
[TBL] [Abstract][Full Text] [Related]
19. A germline mutation (A339V) in thyroid transcription factor-1 (TITF-1/NKX2.1) in patients with multinodular goiter and papillary thyroid carcinoma.
Ngan ES; Lang BH; Liu T; Shum CK; So MT; Lau DK; Leon TY; Cherny SS; Tsai SY; Lo CY; Khoo US; Tam PK; Garcia-Barceló MM
J Natl Cancer Inst; 2009 Feb; 101(3):162-75. PubMed ID: 19176457
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of the MUC1 and MUC4 expressions in thyroid papillary carcinoma.
Baek SK; Woo JS; Kwon SY; Lee SH; Chae YS; Jung KY
Laryngoscope; 2007 May; 117(5):911-6. PubMed ID: 17473695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
